• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Diversey Announces Third Quarter 2022 Results

    11/3/22 7:00:00 AM ET
    $DSEY
    Specialty Chemicals
    Consumer Discretionary
    Get the next $DSEY alert in real time by email
    • Reported sales +3.6% compared to prior year; +17.3% in constant currency
      • Institutional (2%) reported sales and +12% in constant currency
      • Food and Beverage +18% reported sales and +33% in constant currency



    • Net Loss of $36.5 million for the third quarter



      • Adjusted EBITDA was $88.0 million, representing Adjusted EBITDA margin of 12.8%
      • Adjusted EBITDA margin declined (320) basis points compared to prior year; improved by 40 basis points sequentially from the second quarter 2022 and 370 basis points from the first quarter 2022



    • Updating 2022 full year revenue outlook to mid-single digit percent growth; Adjusted EBITDA outlook to at least $330 million to reflect current exchange rate environment and incremental input costs

    FORT MILL, S.C., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Diversey Holdings, Ltd. ("Diversey") (NASDAQ:DSEY) announces third quarter results.

    "We delivered strong top line growth in the quarter of 17% in constant currency, driven by high customer retention, new business wins and accelerating pricing," said Phil Wieland, Diversey's Chief Executive Officer. "We executed well. However, we are operating in an unprecedented environment with underlying results impacted by continued rising inflation and the effect of currency exchange rates associated with a strengthening US dollar. We are pricing for inflation and once the current challenges recede we expect to see revenue and margins improve and accelerate."

    UnauditedThird Quarter Ended September 30
    (millions)2022  2021 % Change 
    Net sales689.0 $664.9 3.6 % 
    Loss before taxes(35.4) (22.9)(54.6)% 
    Net loss(36.5) (42.1)13.3 % 
    Adjusted net income(1)27.6  28.8 (4.2)% 
         
    Adjusted EBITDA(1)88.0  106.6 (17.4)% 
    % Margin(1)12.8% 16.0%(320) bps 

    (1) See the "Non-GAAP Financial Information and Segment Adjusted EBITDA" section herein for explanations of these financial measures.

    Third Quarter 2022 Consolidated Results

    Net sales increased 3.6% versus prior year or 17.3% when adjusting for currency, showing positive momentum in volume growth and pricing. Each segment continues to win new customers while passing through pricing to combat high cost inflation.

    Loss before taxes of $35.4 million in the third quarter of 2022 included Special Items (as defined below) impact of $54.8 million and compared to loss before taxes of $22.9 million in third quarter 2021 including Special Items impact of $57.0 million. Adjusted net income in the third quarter 2022 was $27.6 million compared to $28.8 million in the same quarter 2021 and Adjusted EPS of $0.09 in second quarter 2022 compared to $0.10 in the same quarter 2021.

    In an inflationary environment with increased foreign exchange headwinds, Adjusted EBITDA for the third quarter 2022 was $88.0 million, representing a decline of 17.4% versus the period in 2021 as reported or a decline of 2.5% when adjusting for currency. Adjusted EBITDA margin declined 320 basis points compared to the same period 2021. In the third quarter, pricing accounted for more than 12% revenue growth and the level of pricing is expected to increase further throughout the year. However, accelerating pricing and increased volume were more than offset by higher costs and foreign exchange pressures in the period.

    Segment Review

    Institutional

    UnauditedThird Quarter Ended September 30 
    (millions) 2022  2021 % Change
    Net sales$479.4 $487.2 (1.6)%
    Adjusted EBITDA 68.8  84.3 (18.4)%
    % Margin 14.4% 17.3%(290) bps

    Net sales of $479.4 million in the Institutional segment were 1.6% below Q3 2021 or 11.6% above when adjusting for currency. Growth in the quarter reflects a combination of new client wins, innovation, pricing, and continued expansion with our existing customers as we progress towards a return to pre-pandemic levels. Adjusted EBITDA of $68.8 million declined 18.4% compared to Q3 2021 or 3.4% when adjusting for currency. Adjusted EBITDA margin declined 290 basis points vs Q3 2021 due to cost pressures, but has grown 320 basis points sequentially from Q1 2022 as pricing has gained traction. Acquisitions contributed $12.9 million to sales growth and $1.6 million to Adjusted EBITDA.

    Food & Beverage

    UnauditedThird Quarter Ended September 30 
    (millions) 2022  2021 % Change
    Net sales$209.6 $177.7 18.0 %
    Adjusted EBITDA 26.9  34.3 (21.6)%
    % Margin 12.8% 19.3%(650) bps

    Net sales of $209.6 million in the Food & Beverage segment were 18.0% above Q3 2021 or 32.9% above when adjusting for currency. This strong growth was driven by high win rates, pricing and success with the water treatment offering. Adjusted EBITDA of $26.9 million declined 21.6% and margin declined 650 basis points compared to the same 2021 period, impacted by high input cost inflation, particularly in Europe due to the Russia-Ukraine war. Aggressive pricing actions are being taken to address the price-cost gap and Adjusted EBITDA margins have improved by 100 basis points sequentially from Q1 2022. Acquisitions contributed $13.4 million to sales growth and $1.9 million to Adjusted EBITDA.

    Outlook

    Diversey continues to be encouraged by the resiliency of the core business and the ability to grow while implementing pricing actions reflective of the inflationary environment. The macro background is unpredictable and the volatility in global exchange rates continues to impact the Company's strong execution. Accordingly, Diversey believes it is appropriate to update its full year revenue guide to mid-single digit percent growth over 2021, which would be mid-teen percent growth in constant currency. Diversey is updating its current outlook for Adjusted EBITDA to be at least $330 million to reflect the exchange rate environment and additional input cost headwind.

    About Diversey

    Diversey's mission is to protect and care for people through leading hygiene, infection prevention, and cleaning solutions. We develop and deliver innovative products, services, and technologies that save lives and protect our environment. Over the course of 95 years, the Diversey brand has become synonymous with product quality, service, and innovation.

    For more information about Diversey, visit www.diversey.com or follow us on LinkedIn, Facebook, or Twitter @diversey.

    Diversey Holdings, Ltd.

    Investor Contact:

    Grant Graver

    [email protected]

    Conference Call and Webcast Information

    Management will host a webcast and conference call today, November 3, 2022 at 8:30 am ET to discuss the results for Q3 2022.

    The event will be available live via webcast which can be accessed here. Interested parties may also access the conference call by dialing 1-877-407-0784 (Toll Free) or 1-201-689-8560 (Toll/International) and requesting the Diversey Third Quarter 2022 Earnings Conference Call. Participants are asked to dial in 10 minutes prior to the call in order to register for the event.

    An audio replay of the conference call will be available approximately three hours after the scheduled conference call until 11:59 pm ET on November 17, 2022 and can be accessed by dialing 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and providing the passcode 13730600.

    Cautionary Statements Regarding Forward-Looking Information

    This communication contains forward-looking statements that are subject to substantial risks and uncertainties. All statements other than statements of historical fact included in this communication, including statements regarding our business strategy, future operations and results thereof, future financial position, future revenue, projected costs, prospects, current and prospective products, current and prospective collaborations, timing and likelihood of success, plans and objectives of management, expected market growth and future results of current and anticipated products are forward-looking statements. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "anticipate", "estimate", "expect", "project", "plan", "potential", "predict", "intend", "believe", "may", "might", "will", "would", "should", "can have", "could", "continue", "contemplate", "target", "likely" and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events although not all forward-looking statements contain these identifying words. For example, all statements we make relating to our estimated and projected costs, expenditures, cash flows, growth rates and financial results or our plans and objectives for future operations, growth initiatives, or strategies are forward-looking statements. All forward-looking statements involve unknown risks, and other important factors that may cause actual results performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including:

    • the continuation of the COVID-19 pandemic may cause disruptions to our operations, customer demand, and our suppliers' ability to support us;
    • uncertain global economic conditions which have had and could continue to have an adverse effect on our consolidated financial condition and results of operations;
    • the global nature of our operations exposes us to numerous risks that could materially adversely affect our consolidated financial condition and results of operations;
    • fluctuations between non-U.S. currencies and the U.S. dollar could materially impact our consolidated financial condition or results of operations;
    • political and economic instability and risk of government actions affecting our business and our customers or suppliers may adversely impact our business, results of operations and cash flows;
    • raw material pricing, availability and allocation by suppliers as well as energy-related costs may negatively impact our results of operations, including our profit margins;
    • if we do not develop new and innovative products or if customers in our markets do not accept them, our results would be negatively affected;
    • cyber risks and the failure to maintain the integrity of our operational or security systems or infrastructure;
    • the introduction of the Organization for Economic Cooperation and Development's Base Erosion and Profit Shifting may adversely affect our effective rate of tax in future periods;
    • the consolidation of customers may adversely affect our business, consolidated financial condition or results of operations;
    • we experience competition in the markets for our products and services and in the geographic areas in which we operate;
    • instability and uncertainty in the credit and financial markets could adversely impact the availability of credit that we and our customers need to operate our business;
    • new and stricter regulations may affect our business and consolidated condition and results of operations; and
    • the other risks described under "Risk Factors" in Diversey's Form 10-K filed with the Securities and Exchange Commission.

    We derive many of our forward-looking statements from our operating budgets and forecasts, which are based on many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. All written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by these cautionary statements as well as other cautionary statements that are made from time to time in our other SEC filings and public communications. You should evaluate all forward-looking statements in the context of these risks and uncertainties.

    We caution you that the important factors referenced above may not contain all of the factors that are important to you. In addition, we cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our operations in the way we expect. The forward-looking statements included herein are made only as of the date hereof. We undertake no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

    Non-GAAP Financial Information

    We present financial information that conforms to generally accepted accounting principles in the United States ("U.S. GAAP"). We also present financial information that does not conform to U.S. GAAP ("Non-GAAP"), as our management believes it is useful to investors.

    The Non-GAAP financial metrics exclude items that we consider to be certain specified items ("Special Items"), such as restructuring charges, transaction and integration costs, certain transaction and other charges related to acquisitions and divestitures, gains and losses related to acquisitions and divestitures, and certain other items. We evaluate unusual or Special Items on an individual basis. Our evaluation of whether to exclude an unusual or Special Item for purposes of determining our Non-GAAP financial measures considers both the quantitative and qualitative aspects of the item, including among other things (i) its nature, (ii) whether or not it relates to our ongoing business operations, and (iii) whether or not we expect it to occur as part of our normal business on a regular basis.

    EBITDA and Adjusted EBITDA

    EBITDA and Adjusted EBITDA are supplemental measures that are not required by, or presented in accordance with, U.S. GAAP. We define EBITDA as income (loss) before income tax provisions (benefit), interest expense, and depreciation and amortization, and Adjusted EBITDA, as EBITDA adjusted for other items to (i) eliminate certain non-operating income or expense items, (ii) eliminate the impact of certain non-cash and other items that are included in net income (loss) that we do not consider indicative of our ongoing operating performance, and (iii) eliminate certain unusual and non-recurring items impacting results in a particular period.

    EBITDA and Adjusted EBITDA are not measures of our financial performance under U.S. GAAP and should not be considered as an alternative to revenues, net income (loss), income (loss) before income tax provision or any other performance measures derived in accordance with U.S. GAAP, nor should they be considered as alternatives to cash flows from operating activities as a measure of liquidity in accordance with U.S. GAAP. In addition, our method of calculating EBITDA and Adjusted EBITDA may vary from the methods used by other companies.

    Our management considers EBITDA and Adjusted EBITDA to be key indicators of our financial performance. Additionally, we believe EBITDA and Adjusted EBITDA are frequently used by securities analysts, investors and other interested parties in the evaluation of companies in our industry. We also believe that investors, analysts and rating agencies consider EBITDA and Adjusted EBITDA useful means of measuring our ability to meet our debt service obligations and evaluating our financial performance, and management uses these measures for one or more of these purposes. Our presentation of EBITDA and Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items. EBITDA and Adjusted EBITDA have important limitations as analytical tools and you should not consider them in isolation or as a substitute for analysis of our results as reported under U.S. GAAP. The use of EBITDA and Adjusted EBITDA instead of net income has limitations as an analytical tool.

    Adjusted Net Income

    Adjusted Net Income (as defined below) and Adjusted Earnings (Loss) Per Share ("Adjusted EPS") are Non-GAAP financial measures. We define Adjusted Net Income as net income (loss) adjusted to (i) eliminate certain non-operating income or expense items, (ii) eliminate the impact of certain non-cash and other items that are included in net income that we do not consider indicative of our ongoing operating performance, (iii) eliminate certain unusual and non-recurring items impacting results in a particular period, and (iv) reflect the tax effect of items (i) through (iii) and other tax special items.

    We believe that in addition to our results determined in accordance with GAAP, Adjusted Net Income and Adjusted EPS are useful in evaluating our business, results of operations and financial condition. We believe that Adjusted Net Income and Adjusted EPS may be helpful to investors because they provide consistency and comparability with past financial performance and facilitate period to period comparisons of our operations and financial results, as they eliminate the effects of certain variables from period to period for reasons that we do not believe reflect our underlying operating performance or are unusual or infrequent in nature. However, Adjusted Net Income and Adjusted EPS are presented for supplemental informational purposes only and should not be considered in isolation or as a substitute or alternative for financial information presented in accordance with GAAP.

    Adjusted Net Income and Adjusted EPS have limitations as analytical tools.



    Diversey Holdings, Ltd.

    Condensed Consolidated Balance Sheets

    (Unaudited)

    (in millions except per share amounts)September 30, 2022December 31, 2021
    Assets  
    Current assets:  
     Cash and cash equivalents$249.1 $207.6 
     Trade receivables, net of allowance for doubtful accounts of $22.0 and $23.5 416.4  414.3 
     Other receivables 68.2  59.3 
     Inventories 368.7  337.6 
     Prepaid expenses and other current assets 121.7  69.4 
      Total current assets 1,224.1  1,088.2 
    Property and equipment, net 226.6  210.7 
    Goodwill 441.4  471.5 
    Intangible assets, net 1,869.7  2,147.3 
    Other non-current assets 381.2  382.3 
      Total assets$4,143.0 $4,300.0 
        
    Liabilities and stockholders' equity  
    Current liabilities:  
     Short-term borrowings$6.6 $10.7 
     Current portion of long-term debt 11.5  10.9 
     Accounts payable 479.2  434.3 
     Accrued restructuring costs 14.0  16.7 
     Other current liabilities 393.9  384.5 
      Total current liabilities 905.2  857.1 
    Long-term debt, less current portion 1,969.9  1,973.0 
    Deferred taxes 151.0  164.3 
    Other non-current liabilities 450.8  520.0 
      Total liabilities 3,476.9  3,514.4 
    Commitments and contingencies  
    Stockholders' equity:  
     Ordinary shares, $0.01 par value per share; 1,000,000,000 shares authorized, 324,315,963 and 324,369,517 shares outstanding in 2022 and 2021 —  — 
     Preferred shares, $0.0001 par value per share, 200,000,000 shares authorized, 0 shares outstanding in 2022 and 2021 —  — 
     Additional paid-in capital 1708.1  1,662.7 
     Accumulated deficit (829.9) (720.1)
     Accumulated other comprehensive loss (212.1) (157.0)
      Total stockholders' equity 666.1  785.6 
     Total liabilities and stockholders' equity$4,143.0 $4,300.0 



    Diversey Holdings, Ltd.

    Condensed Consolidated Statements of Operations

    (Unaudited)

     Three Months Ended

    September 30,
    Nine Months Ended

    September 30,
    (in millions except per share amounts) 2022  2021  2022  2021 
    Net sales$689.0 $664.9 $2,064.3 $1,946.5 
    Cost of sales 447.3  405.2  1,349.5  1,174.8 
    Gross profit 241.7  259.7  714.8  771.7 
    Selling, general and administrative expenses 191.3  193.2  614.7  642.5 
    Transaction and integration costs 12.5  4.4  26.1  24.6 
    Management fee —  —  —  19.4 
    Amortization of intangible assets 21.5  24.2  68.5  72.6 
    Restructuring and exit costs 39.4  21.6  67.6  29.6 
    Operating income (loss) (23.0) 16.3  (62.1) (17.0)
    Interest expense 25.7  25.8  83.0  97.4 
    Foreign currency gain related to hyperinflationary subsidiaries (2.0) (2.9) (3.6) (2.7)
    Loss on extinguishment of debt —  15.6  —  15.6 
    Other (income) expense, net (11.3) 0.7  (35.2) 4.8 
    Loss before income tax provision (35.4) (22.9) (106.3) (132.1)
    Income tax provision 1.1  19.2  3.5  7.0 
    Net loss$(36.5)$(42.1)$(109.8)$(139.1)
         
    Basic and diluted loss per share$(0.11)$(0.14)$(0.34)$(0.49)
    Basic and diluted weighted average shares outstanding 320.2  301.6  319.9  283.4 



    Diversey Holdings, Ltd.

    Condensed Consolidated Statements of Cash Flows

    (Unaudited)

    (in millions)Nine Months Ended

    September 30, 2022
    Nine Months Ended

    September 30, 2021
    Operating activities:  
     Net loss$(109.8)$(139.1)
     Adjustments to reconcile net loss to cash provided by (used in) operating activities:  
     Depreciation and amortization 138.2  141.6 
     Amortization of deferred financing costs and original issue discount 5.4  21.6 
     Loss on extinguishment of debt —  15.6 
     (Gain) loss on derivatives (0.6) 2.3 
     Deferred taxes (17.6) (15.6)
     Non-cash foreign currency exchange (gain) loss (8.9) 5.2 
     Share-based compensation 45.4  67.1 
     Impact of highly inflationary subsidiaries (3.6) (2.7)
     Provision for (recovery of) bad debts 2.8  (1.9)
     Provision for slow moving inventory 16.2  4.1 
     Non-cash pension benefit (10.3) (12.0)
     Non-cash restructuring and exit costs —  16.9 
     Non-cash tax receivable agreement adjustments (16.7) 4.1 
     Changes in operating assets and liabilities:  
     Trade receivables, net (58.3) (96.8)
     Inventories, net (72.4) (52.8)
     Accounts payable 95.6  1.9 
     Income taxes, net (11.0) (5.8)
     Other assets and liabilities, net 40.0  (64.6)
    Cash provided by (used in) operating activities 34.4  (110.9)
    Investing activities:  
     Business acquired in purchase transactions, net of cash acquired (41.4) (9.4)
     Acquisition of intellectual property —  (3.0)
     Dosing and dispensing equipment (57.7) (47.8)
     Capital expenditures (36.2) (22.2)
     Collection of deferred factored receivables —  40.1 
    Cash used in investing activities (135.3) (42.3)
    Financing activities:  
     Contingent consideration payments —  (0.3)
     Proceeds from (payments on) short-term borrowings (2.8) 16.7 
     Proceeds from revolving credit facility 50.0  109.0 
     Payments on revolving credit facility (50.0) (109.0)
     Proceeds from long-term borrowings —  2,000.0 
     Payments on long-term borrowings (13.2) (2,667.8)
     Payment of deferred financing costs —  (35.1)
     Payment of bond redemption premium —  (7.6)
     Issuance of ordinary shares sold in IPO, net of offering costs —  725.7 
     Proceeds from termination of derivatives 186.1  — 
    Cash provided by financing activities 170.1  31.6 
    Exchange rate changes on cash (27.7) (4.0)
     Increase (decrease) in cash, cash equivalents and restricted cash 41.5  (125.6)
    Cash, cash equivalents and restricted cash at beginning of period 208.2  201.7 
    Cash, cash equivalents and restricted cash at end of period$249.7 $76.1 
       
    Supplemental Cash Flow Information:  
     Interest payments$57.8 $99.3 
     Income tax payments$33.5 $27.0 
     Conversion of preferred equity certificates to equity$— $620.9 
     Beneficial interest obtained for factored receivables$— $25.6 

    The following table reconciles loss before income tax provision to EBITDA and Adjusted EBITDA for the periods presented:

     Three Months Ended September 30,
    (in millions) 2022  2021 
    Loss before income tax provision$(35.4)$(22.9)
    Interest expense 25.7  25.8 
    Interest income (1.4) (0.8)
    Amortization expense of intangible assets 21.5  24.2 
    Depreciation expense included in cost of sales 20.6  20.4 
    Depreciation expense included in selling, general and administrative expenses 2.2  2.9 
    EBITDA 33.2  49.6 
    Transaction and integration costs(1) 12.5  4.4 
    Restructuring and exit costs(2) 39.4  21.6 
    Foreign currency (gain) loss related to hyperinflationary subsidiaries(3) (2.0) (2.9)
    Adjustment for tax indemnification asset(4) 0.3  0.1 
    Acquisition accounting adjustments(5) —  — 
    Bain Capital management fee(6) —  — 
    Non-cash pension and other post-employment benefit plan(7) (3.3) (4.3)
    Unrealized foreign currency exchange (gain) loss(8) (3.6) (2.4)
    Factoring and securitization fees(9) 1.7  1.4 
    Share-based compensation(10) 13.9  16.0 
    Tax receivable agreement adjustments(11) (3.7) — 
    Loss on extinguishment of debt(12) —  15.6 
    Realized foreign currency exchange loss on debt refinancing(13) —  4.5 
    COVID-19 inventory charges(14) —  — 
    Other items (0.4) 3.0 
    Consolidated Adjusted EBITDA$88.0 $106.6 



     Nine Months Ended September 30,
    (in millions) 2022  2021 
    Loss before income tax provision$(106.3)$(132.1)
    Interest expense 83.0  97.4 
    Interest income (2.8) (2.9)
    Amortization expense of intangible assets 68.5  72.6 
    Depreciation expense included in cost of sales 62.1  62.0 
    Depreciation expense included in selling, general and administrative expenses 7.6  6.9 
    EBITDA 112.1  103.9 
    Transaction and integration costs(1) 26.1  24.6 
    Restructuring and exit costs(2) 67.6  29.6 
    Foreign currency (gain) loss related to hyperinflationary subsidiaries(3) (3.6) (2.7)
    Adjustment for tax indemnification asset(4) 0.7  1.4 
    Acquisition accounting adjustments(5) 1.3  — 
    Bain Capital management fee(6) —  19.4 
    Non-cash pension and other post-employment benefit plan(7) (10.3) (12.0)
    Unrealized foreign currency exchange (gain) loss(8) (8.9) 5.2 
    Factoring and securitization fees(9) 3.9  3.6 
    Share-based compensation(10) 46.7  99.3 
    Tax receivable agreement adjustments(11) (16.7) 4.1 
    Loss on extinguishment of debt(12) —  15.6 
    Realized foreign currency exchange loss on debt refinancing(13) —  4.5 
    COVID-19 inventory charges(14) 17.4  — 
    Other items 0.4  4.1 
    Consolidated Adjusted EBITDA$236.7 $300.6 

    The following table reconciles net loss to Adjusted Net Income and basic and diluted earnings (loss) per share to Adjusted EPS for the periods presented:

     Three Months Ended September 30,
      2022  2021  
    (in millions, except per share amounts)Net Income

    (Loss)
    Basic and

    diluted EPS
    (18)
    Net Income

    (Loss)
    Basic and

    diluted EPS
    (18)
     
    Reported (GAAP)$(36.5)$(0.11)$(42.1)$(0.14) 
    Amortization expense of intangible assets acquired 21.5  0.07  24.2  0.08  
    Transaction and integration costs(1) 12.5  0.04  4.4  0.01  
    Restructuring and exit costs(2) 39.4  0.12  21.6  0.07  
    Foreign currency (gain) loss related to hyperinflationary subsidiaries(3) (2.0) (0.01) (2.9) (0.01) 
    Adjustment for tax indemnification asset(4) 0.3  —  0.1  —  
    Acquisition accounting adjustments(5) —  —  —  —  
    Bain Capital management fee(6) —  —  —  —  
    Non-cash pension and other post-employment benefit plan(7) (3.3) (0.01) (4.3) (0.01) 
    Unrealized foreign currency exchange (gain) loss(8) (3.6) (0.01) (2.4) (0.01) 
    Share-based compensation(10) 13.9  0.04  16.0  0.05  
    Tax receivable agreement adjustments(11) (3.7) (0.01) —  —  
    Loss on extinguishment of debt(12) —  —  15.6  0.05  
    Realized foreign currency exchange loss on debt refinancing(13) —  —  4.5  0.01  
    COVID-19 inventory charges(14) —  —  —  —  
    Accelerated expense of deferred financing and original issue discount costs(15) —  —  —  —  
    Other items (0.4) —  3.0  0.01  
    Tax effects related to non-GAAP adjustments(16) (23.3) (0.07) (18.2) (0.04) 
    Discrete tax adjustments(17) 12.8  0.04  9.3  0.03  
    Adjusted (Non-GAAP)$27.6 $0.09 $28.8 $0.10  



     Nine Months Ended September 30,
      2022  2021  
    (in millions, except per share amounts)Net Income

    (Loss)
    Basic and

    diluted EPS
    (18)
    Net Income

    (Loss)
    Basic and

    diluted EPS
    (18)
     
    Reported (GAAP)$(109.8)$(0.34)$(139.1)$(0.49) 
    Amortization expense of intangible assets acquired 68.5  0.21  72.6  0.26  
    Transaction and integration costs(1) 26.1  0.08  24.6  0.09  
    Restructuring and exit costs(2) 67.6  0.21  29.6  0.10  
    Foreign currency (gain) loss related to hyperinflationary subsidiaries(3) (3.6) (0.01) (2.7) (0.01) 
    Adjustment for tax indemnification asset(4) 0.7  —  1.4  —  
    Acquisition accounting adjustments(5) 1.3  —  —  —  
    Bain Capital management fee(6) —  —  19.4  0.07  
    Non-cash pension and other post-employment benefit plan(7) (10.3) (0.03) (12.0) (0.04) 
    Unrealized foreign currency exchange (gain) loss(8) (8.9) (0.03) 5.2  0.02  
    Share-based compensation(10) 46.7  0.15  99.3  0.35  
    Tax receivable agreement adjustments(11) (16.7) (0.05) 4.1  0.01  
    Loss on extinguishment of debt(12) —  —  15.6  0.06  
    Realized foreign currency exchange loss on debt refinancing(13) —  —  4.5  0.02  
    COVID-19 inventory charges(14) 17.4  0.05  —  —  
    Accelerated expense of deferred financing and original issue discount costs(15) —  —  14.0  0.05  
    Other items 0.4  —  4.1  0.01  
    Tax effects related to non-GAAP adjustments(16) (49.0) (0.14) (42.6) (0.16) 
    Discrete tax adjustments(17) 29.7  0.09  2.6  0.01  
    Adjusted (Non-GAAP)$60.1 $0.19 $100.6 $0.35  

    (1) These costs consist primarily of professional and consulting services which are non-operational in nature, costs related to strategic initiatives, acquisition-related costs, and costs incurred in preparing to become a publicly traded company.

    (2) Includes costs related to restructuring programs and business exit activities. Refer to Note 16 — Restructuring and Exit Activities in the Notes to our Condensed Consolidated Financial Statements included elsewhere in the Quarterly Report on Form 10-Q for additional information.

    (3) Argentina and Turkey were deemed to have highly inflationary economies and the functional currencies for our Argentina and Turkey operations were changed from the Argentine peso and Turkish lira to the United States dollar and remeasurement charges/credits are recorded in our Condensed Consolidated Statements of Operations rather than as a component of Cumulative Translation Adjustment on our Condensed Consolidated Balance Sheets.

    (4) In connection with the Diversey Acquisition, the purchase agreement governing the transaction includes indemnification provisions with respect to tax liabilities. The offset to this adjustment is included in income tax provision.

    (5) In connection with various acquisitions we recorded fair value increases to our inventory. These amounts represent the amortization of this increase.

    (6) Represents fees paid to Bain Capital pursuant a management agreement whereby we have received general business consulting services; financial, managerial and operational advice; advisory and consulting services with respect to selection of advisors; advice in different fields; and financial and strategic planning and analysis. The management agreement was terminated in March 2021 pursuant to its terms upon the consummation of the IPO, and we recorded a termination fee of $17.5 million during the first quarter of 2021.

    (7) Represents the net impact of the expected return on plan assets, interest cost, and settlement cost components of net periodic defined benefit income related to our defined benefit pension plans.

    (8) Represents the unrealized foreign currency exchange impact on our operations, primarily attributed to the valuation of the U.S. Dollar-denominated debt held by our European entity.

    (9) Represents the fees to complete the sale of the receivables without recourse under our accounts receivable factoring and securitization agreements. Refer to Note 5 — Financial Statement Details in the Notes to our Condensed Consolidated Financial Statements included elsewhere in the Quarterly Report on Form 10-Q for additional information.

    (10) Represents compensation expense associated with our share-based equity and liability awards. See Note 15 — Share-Based Compensation in the Notes to our Condensed Consolidated Financial Statements included elsewhere in the Quarterly Report on Form 10-Q for additional information.

    (11) Represents the adjustment to our tax receivable agreement liability due to changes in valuation allowances that impact the realizability of the attributes of the tax receivable agreement.

    (12) Represents the costs incurred in connection with the redemption of the 2017 Senior Notes on September 29, 2021.

    (13) During 2021, the Company incurred a realized foreign currency exchange loss related to the refinancing of the Senior Secured Credit Facilities.

    (14) Represents a charge in the second quarter of 2022 for excess inventory and estimated disposal costs related to COVID-19.

    (15) Represents accelerated non-cash expense of deferred financing costs and original issue discount costs as certain debt facilities were fully repaid or paid down significantly in March 2021 using proceeds from the IPO.

    (16) The tax rate used to calculate the tax impact of the pre-tax adjustments is based on the jurisdiction in which the charge was recorded.

    (17) Represents adjustments related to discrete tax items including uncertain tax provisions, impacts from rate changes in certain jurisdictions and changes in our valuation allowance.

    (18) For purposes of calculating earnings (loss) per share the Company has retrospectively presented earnings (loss) per share as if the Reorganization Transactions had occurred at the beginning of the earliest period presented. Such retrospective presentation reflects an increase of approximately 47.4 million shares due to the exchange of shares in Constellation for shares in the Company.

    The following table represents net sales by segment:

    (in millions, except percentages) InstitutionalFood & BeverageTotal
    Q3 2021 Net Sales$487.2 73.3 %$177.7 26.7 %$664.9  
    Organic change (non-GAAP) 43.6 8.9 % 45.1 25.4 % 88.7 13.3 %
    Acquisition 12.9 2.6 % 13.4 7.5 % 26.3 4.0 %
    Constant dollar change (non-GAAP) 56.5 11.6 % 58.5 32.9 % 115.0 17.3 %
    Foreign currency translation (64.3)(13.2)% (26.6)(15.0)% (90.9)(13.7)%
    Total change (7.8)(1.6)% 31.9 18.0 % 24.1 3.6 %
    Q3 2022 Net Sales$479.4 69.6 %$209.6 30.4 %$689.0  


    Primary Logo

    Get the next $DSEY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DSEY

    DatePrice TargetRatingAnalyst
    2/22/2023$6.00Underperform
    BofA Securities
    12/15/2022$5.80Market Perform
    BMO Capital Markets
    10/5/2022Buy → Neutral
    Citigroup
    6/16/2022$12.00 → $10.00Buy → Hold
    Jefferies
    5/20/2022$11.00 → $12.00Outperform
    Credit Suisse
    3/25/2022$11.00 → $9.00Outperform → Sector Perform
    RBC Capital Mkts
    3/11/2022$19.00 → $15.00Overweight
    Morgan Stanley
    3/11/2022$14.00 → $11.00Outperform
    RBC Capital
    More analyst ratings

    $DSEY
    Leadership Updates

    Live Leadership Updates

    See more
    • Diversey Announces Appointment of Eric Foss as Chairman of the Board

      FORT MILL, S.C., March 17, 2022 (GLOBE NEWSWIRE) -- Diversey Holdings, Ltd. (NASDAQ:DSEY), a leading provider of hygiene, infection prevention and cleaning solutions, today announced that its Board of Directors has appointed Eric Foss as Chairman of the Board effective March 17. Foss succeeds Selim Bassoul who will remain a Director. Mr. Foss has been a Director since Diversey's IPO in March 2021. "Eric is a highly successful leader, with a proven track record of driving growth, creating sustainable shareholder value, building high performance teams and creating a purpose driven legacy for global at scale companies," said Phil Wieland, Diversey's CEO. "I look forward to continuing to w

      3/17/22 8:30:00 AM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary
    • Diversey Appoints Katherine S. Zanotti to its Board of Directors

      FORT MILL, S.C., March 01, 2022 (GLOBE NEWSWIRE) -- Diversey Holdings, Ltd. (NASDAQ:DSEY), a leading provider of hygiene, infection prevention and cleaning solutions, has appointed Katherine S. Zanotti to the company's board of directors, effective March 1, 2022. This appointment will bring the total number of directors to eleven. "We are delighted to welcome Katherine (‘Kay') to our board. Kay's long history of leadership coupled with her extensive experience in sales and marketing within the foodservice and health care sectors makes her a great addition and helps position Diversey for continued growth and success," said Phil Wieland, CEO of Diversey.     Katherine S. Zanotti served as

      3/1/22 8:30:00 AM ET
      $CUTR
      $DSEY
      $EXAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Specialty Chemicals
      Consumer Discretionary
    • Diversey Appoints Rod Hochman, M.D. to its Board of Directors

      FORT MILL, S.C., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Diversey Holdings, Ltd. (NASDAQ:DSEY), a leading provider of hygiene, infection prevention and cleaning solutions, has appointed Rod Hochman, M.D. to the company's board of directors, effective September 1, 2021. This appointment will bring the total number of directors to ten. "We are extremely pleased to welcome Rod to our board," said Phil Wieland, CEO of Diversey. "His extensive background in the healthcare sector makes Rod a great addition and helps position Diversey for continued growth and success in that area."     Rod Hochman, M.D. has been the President and Chief Executive Officer of Providence, a not-for-profit health system s

      9/1/21 8:18:44 AM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary

    $DSEY
    Financials

    Live finance-specific insights

    See more

    $DSEY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Diversey Reports First Quarter 2023 Results

      Reported sales +5.5% compared to prior year; +12.6% adjusted for constant currencyLoss before taxes of $44.3 million for the first quarter, representing loss before taxes margin of (6.4)% Adjusted EBITDA was $52.6 million, representing Adjusted EBITDA margin of 7.6% FORT MILL, S.C., May 04, 2023 (GLOBE NEWSWIRE) -- Diversey Holdings, Ltd. ("Diversey") (NASDAQ:DSEY) announces first quarter results. UnauditedFirst Quarter Ended March 31(millions) 2023  2022 % ChangeNet sales$696.0 $660.0 5.5%Loss before taxes (44.3) (37.2)(19.1)%% Margin(6.4)%(5.6)%(80) bpsNet loss (53.6) (39.1)(37.1)%Adjusted net income (loss)(1) 1.5  3.7 (59.5)%    Adjusted EBITDA(1) 52.6  60.3 (12.8)%% Margin(1) 7.6% 9.

      5/4/23 7:59:00 AM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary
    • Diversey Reports Fourth Quarter and Full Year 2022 Results

      Reported sales +4.3% in the fourth quarter compared to prior year and full year 2022 reported sales +5.6%Net loss of $59.5 million for the fourth quarter and $169.3 million for full year 2022 Fourth quarter Adjusted EBITDA was $93.4 million, representing Adjusted EBITDA margin of 13.3%Full year Adjusted EBITDA was $330.1 million, representing Adjusted EBITDA margin of 11.9% FORT MILL, S.C., March 17, 2023 (GLOBE NEWSWIRE) -- Diversey Holdings, Ltd. ("Diversey") (NASDAQ:DSEY) announced fourth quarter and full year results.  Year Ended December 31(millions) 2022  2021 % ChangeNet sales$2,765.9 $2,618.9 5.6%Loss before taxes (185.5) (149.5)(24.1)%Net loss (169.3) (174.8)3.1%Adjusted net inc

      3/17/23 4:29:28 PM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary
    • Diversey to be Acquired by Solenis for $4.6 Billion

      Diversey Public Shareholders to Receive $8.40 Per Share in Cash in "Go Private" Transaction Combined company will allow for expanded markets and additional sustainable solutions Solenis ("Solenis") and Diversey Holdings, Ltd. ("Diversey" or the "Company") (NASDAQ:DSEY) today announced they have entered into a definitive merger agreement under which Solenis will acquire Diversey in an all-cash transaction valued at an enterprise value of approximately $4.6 billion. Upon completion of the merger, Diversey will become a private company. Under the terms of the agreement, Diversey shareholders (other than shareholders affiliated with Bain Capital Private Equity ("Bain Capital")) will receive

      3/8/23 6:59:00 AM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary
    • New Study from Diversey shows that contact time and disinfectant formulation has a significant impact on the efficacies of disinfectant towelettes on hard, non-porous surfaces

      UTRECHT, Netherlands, June 7, 2023 /PRNewswire/ -- Diversey Holdings, Ltd. (NASDAQ:DSEY), a leading provider of hygiene, infection prevention, and cleaning solutions has demonstrated in a recent study by Purdue University that disinfectant efficacy against Candida auris (C. auris) varied significantly with both product formula and contact time having a significant impact on disinfectant efficacy. The study suggests that healthcare facilities wanting the best hygiene outcomes should use disinfectants with an EPA approved label claim against C. auris and should ensure the surface is kept wet for the contact time listed on the label.

      6/7/23 4:00:00 AM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary
    • Diversey Reports First Quarter 2023 Results

      Reported sales +5.5% compared to prior year; +12.6% adjusted for constant currencyLoss before taxes of $44.3 million for the first quarter, representing loss before taxes margin of (6.4)% Adjusted EBITDA was $52.6 million, representing Adjusted EBITDA margin of 7.6% FORT MILL, S.C., May 04, 2023 (GLOBE NEWSWIRE) -- Diversey Holdings, Ltd. ("Diversey") (NASDAQ:DSEY) announces first quarter results. UnauditedFirst Quarter Ended March 31(millions) 2023  2022 % ChangeNet sales$696.0 $660.0 5.5%Loss before taxes (44.3) (37.2)(19.1)%% Margin(6.4)%(5.6)%(80) bpsNet loss (53.6) (39.1)(37.1)%Adjusted net income (loss)(1) 1.5  3.7 (59.5)%    Adjusted EBITDA(1) 52.6  60.3 (12.8)%% Margin(1) 7.6% 9.

      5/4/23 7:59:00 AM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary
    • New study from Diversey shows that different choices of manual floor mopping materials provide different hygiene outcomes

      UTRECHT, Netherlands, April 24, 2023 /PRNewswire/ -- Diversey Europe Operations B.V. (NASDAQ:DSEY), a leading provider of hygiene, infection prevention, and cleaning solutions recently published a study to demonstrate the importance of floor disinfection in reducing risks associated with floor hygiene. The Authors of the study suggest that commercial facilities wanting the best hygiene outcomes and using manual floor mopping as part of their facility hygiene program should consider the use of biocidal floor products with either launderable or disposable flat mops and avoid the use of cotton string mops and neutral cleaners.

      4/24/23 4:00:00 AM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary

    $DSEY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Diversey Holdings Ltd.

      SC 13G - Diversey Holdings, Ltd. (0001831617) (Subject)

      2/14/22 4:17:18 PM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary

    $DSEY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Hanau Kenneth

      4 - Diversey Holdings, Ltd. (0001831617) (Issuer)

      7/6/23 4:16:06 PM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Bain Capital Investors Llc

      4 - Diversey Holdings, Ltd. (0001831617) (Issuer)

      7/6/23 4:12:03 PM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Levine Susan Bruno

      4 - Diversey Holdings, Ltd. (0001831617) (Issuer)

      7/6/23 4:09:56 PM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary

    $DSEY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities resumed coverage on Diversey Holdings with a new price target

      BofA Securities resumed coverage of Diversey Holdings with a rating of Underperform and set a new price target of $6.00

      2/22/23 6:12:34 AM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary
    • BMO Capital Markets initiated coverage on Diversey Holdings with a new price target

      BMO Capital Markets initiated coverage of Diversey Holdings with a rating of Market Perform and set a new price target of $5.80

      12/15/22 7:41:26 AM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary
    • Diversey Holdings downgraded by Citigroup

      Citigroup downgraded Diversey Holdings from Buy to Neutral

      10/5/22 9:04:01 AM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary

    $DSEY
    SEC Filings

    See more
    • SEC Form 15-12G filed by Diversey Holdings Ltd.

      15-12G - Diversey Holdings, Ltd. (0001831617) (Filer)

      7/17/23 4:06:15 PM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13E3/A filed by Diversey Holdings Ltd. (Amendment)

      SC 13E3/A - Diversey Holdings, Ltd. (0001831617) (Subject)

      7/5/23 5:13:11 PM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form S-8 POS filed by Diversey Holdings Ltd.

      S-8 POS - Diversey Holdings, Ltd. (0001831617) (Filer)

      7/5/23 4:23:44 PM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary